The Federal Trade Commission sued the three dominant pharmacy-benefit managers in the United States, alleging they inflated the cost of insulin by using their position as middlemen in the U.S. drug supply chain to win a higher cut of funds from drugmakers.
top of page
bottom of page
Comments